Abstract | BACKGROUND: OBJECTIVE: To measure the sBCMA level in 165 subjects to determine whether it differentiates severe PAD-CVID and XLA-from less severe forms not requiring IRT and those without PAD. METHODS: sBCMA, B cells, and tissue plasma cells were measured among subjects with and without PAD, and correlated to clinical and laboratory data. RESULTS: Subjects with an IgG level of less than 600 mg/dL had reduced sBCMA levels compared with subjects with PAD with IgG levels of greater than or equal to 600 mg/dL and controls without PAD. sBCMA level was lower in patients with CVID and XLA compared with patients with IgA or IgG deficiency and controls. sBCMA level correlated with gastrointestinal plasma cells. sBCMA level of less than 15 ng/mL had 97% positive predictive value for CVID or XLA, whereas 25 ng/mL or more had an 88% negative predictive value. CONCLUSIONS: sBCMA level is profoundly reduced in patients with severe PAD, including those with CVID and XLA and those with IgG levels of less than 600 mg/dL. sBCMA level measurement has potential to augment clinical evaluation of PAD. Prospective studies are needed to evaluate sBCMA for new PAD diagnosis and determine the necessity of IRT.
|
Authors | Paul J Maglione, Huaibin M Ko, Minami Tokuyama, Gavin Gyimesi, Camilia Soof, Mingjie Li, Eric Sanchez, Haiming Chen, Lin Radigan, James Berenson, Charlotte Cunningham-Rundles |
Journal | The journal of allergy and clinical immunology. In practice
(J Allergy Clin Immunol Pract)
Vol. 8
Issue 1
Pg. 283-291.e1
(01 2020)
ISSN: 2213-2201 [Electronic] United States |
PMID | 31430592
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- B-Cell Maturation Antigen
|
Topics |
- Agammaglobulinemia
(diagnosis)
- B-Cell Maturation Antigen
- Common Variable Immunodeficiency
(diagnosis)
- Humans
- Primary Immunodeficiency Diseases
- Prospective Studies
|